Stock MNPR MONOPAR THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
0.94 USD +2.81% Intraday chart for Monopar Therapeutics Inc. +15.91% +176.31%
May. 24 Monopar Therapeutics Names Karthik Radhakrishnan as CFO MT
May. 24 Monopar Therapeutics Inc. Announces CFO Changes CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Monopar and NorthStar Amend & Extend Collaboration
GL
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
GL
Monopar Therapeutics Names Karthik Radhakrishnan as CFO
MT
Monopar Announces CFO Succession
GL
Monopar Therapeutics Inc. Announces CFO Changes
CI
Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
GL
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
GL
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
AQ
Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct
MT
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
GL
Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
CI
North American Morning Briefing : Big Banks Kick -2-
DJ
JonesTrading Upgrades Monopar Therapeutics to Buy From Hold, Price Target is $2
MT
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
GL
Monopar Therapeutics Inc Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
CI
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
GL
Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
AQ
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNPR Stock
  4. News Monopar Therapeutics Inc.